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ABSTRACT
للمصابني  احلياة  قيد  على  البقاء  حتديد  أجل  من  األهداف:    
الصلة  ذات  والعوامل  الدم  نقل  في عملية   BT الكبرى  بالثالسيميا 
في اجلنوب الشرقي بإيران.
الطريقة:  أجريت هذه الدراسة املقطعية في مدينة زهدان – إيران، 
الذين مت حتويلهم  املرضى  العينات على  اشتملت  2007م.   في عام 
1998م  بني  ما  للثالسيميا،  زهدان  مركز  إلى  املقاطعة  جميع  من 
وحتى 2006م.  مت جمع البيانات بالرجوع إلى ملفات املرضى التي مت 
تسجيلها بواسطة املوظفني أثناء عملية نقل الدم.  شملت البيانات 
املنقول  الدم  RH، ونوع  الدم  والطبية، وفصيلة  اجلغرافية  املعلومات 
ANOT، واألمراض احملمولة  السنوية  النقل  KTB، وعدد عمليات 
استخدام طريقة  فيريتني.  مت  Hb، ومستوى  والهيموجلوبني   ،AD
لتحليل  كوكس  تراجع  اختبار  مع  الرتب  واختبار  ماير   _ كابلني 
البيانات.  
في  جنو  و99%  مريضاً،   578 بني  من  مريضًاُ   46 توفي  النتائج:  
السنة األولى . بلغت نسبة النجاة عند األعمار: اخلامسة - العاشرة 
- اخلامسة عشر والعشرين عامًا %97.9 - %97 – %92.1 و81.2% 
على التوالي.  كان لوقت البقاء على قيد احلياة عالقة ملحوظة مع عدد 
مرات نقل الدم السنوية  ANOT (p=0.0053 ، ونوعية الدم املنقول 
ومستوى   ،  Hb (p=0.002 والهيموجلوبني   ،  KTB (p=0.003
.AD (p=0.000 واألمراض احملمولة ،(p=0.0087( فيريتني
خامتة:  إن استخدام عملية نقل الدم املنتظمة، واالنتباه لفحص الدم 
اإلصابة  احتمال  ملنع  األمراض  العوائل حول  معرفة  من  يزيد  املنقول 
بالثالسيميا في اجلنني.  أخيراً يعد اكتشاف ومعاجلة األمراض احملمولة 
ذو أهمية قصوا إلطالة فترة البقاء على قيد احلياة للمريض.
Objective: To determine the survival of beta-
thalassemia major patients with transfusion, and its 
related factors in Southeast of Iran.
Methods: This cross-sectional study was performed 
in Zahedan, Iran, in 2007. The sample included 
patients who were referred from all over the Zahedan 
Thalassemia Center from 1998 to 2006.  The data 
were collected using the patients’ records, which 
were recorded by the staff during transfusion. The 
data included demographic and medical information 
(blood group, blood RH, the kind of transfused blood 
[KTB], annual number of transfusions [ANOT], 
accompanied diseases [AD], Hemoglobin [Hb] and 
ferritin level). For data analysis, the Kaplan-Meyer 
method, and Log Rank test together with Cox 
Regression were used.
Results: Forty-six of 578 patients died and 99% 
had survived for the first year. The ages survival 
proportions were 5 (97.9%), 10 (97%), 15 (92.1%), 
and 20 (81.2%) years. The survival time showed 
significant relationships with the ANOT  (p=0.0053), 
KTB (p=0.003), Hb (p=0.002) and ferritin level 
(p=0.0087), and AD (p=0.000). 
Discussion: Using regular transfusion, paying 
attention to screening of transfused blood, increasing 
the families’ knowledge on the disease to prevent the 
bearing of thalassemia fetus, are recommended; finally, 
the detection and treating of the AD, are of great 
importance to extend the lifetime of the patients.
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Beta-thalassemia (BT) major is a severe hemolytic anemia, inheritable from parents who are carriers 
of BT minor. The anemia occurs in the early years of 
life and is usually accompanied by splenomegaly and 
bone changes.1 The most common treatments of this 
disease include blood transfusion and bone marrow 
transplantation; though the latter is less attentive due 
to complications, inappropriate donors, high cost and 
possible failure. Iran is located on the thalassemia world 
belt with the highest prevalence of thalassemia over the 
world.2,3 It is estimated that the rate of the thalassemia 
carriers in different provinces of Iran, is ranged between 
1-10% with an average of 4.5%.4 According to the 
formal statistics which are introduced by the Iranian 
health authorities, the number of beta thalassemia major 
patients are more than 20000.5 In the province of Sistan 
& Baluchestan, Southeast of Iran, the number of beta 
thalassemia major patients was 51.9 per 100000 in 1998 
that was increased to 59.4 per 100000 by 2001, which 
gives it the fourth place in the country.5 According to 
the hereditary pattern of beta thalassemia minor and 
the social acceptability of inter-familial marriages, the 
marriage of carriers increases the prevalence of beta 
thalassemia minor to 50% of the population.6 Therefore, 
in S&B province, the prevalence of beta thalassemia 
major (7%) is more than the average of the country 
which is 4%. It is even more than 7% in 2 towns of the 
province, Khash and Iranshahr.7  The most important 
consequent of the disease is shortening of the patients’ 
life. However, the patients’ survival with may concern 
to some factors such as gender, ethnicity, and different 
level of the disease is unknown. In a study in Greece, 
the survival of these patients was 22.6 years.7 
In another research in the North of Iran, 1010 
thalassemic patients were divided into 2 groups 
according to their date of birth, before and after 1986. 
The survival rate of the 2 groups was 68% and 80% 
by the age of 30.8 In a recent study in Canada it was 
proved that patients with the ferritin level of less than 
2500 (gr/dl) have survived longer.9 In another study in 
Taiwan, the researchers showed that the survival of the 
patients born after 1980 is better than others. Also, they 
demonstrated that patients under 15 years old had no 
complications.10 A study in England showed that almost 
half of the patients had survived by the age of 35.11 In 
the province of Hormozgan in South of Iran, it was 
found that 99% of the patients were alive until the age 
of 5, 93% were alive until the age of 10, 68% were alive 
until the age 20 and the survival age for half of them was 
30 years.12 It seems that preventing marriage between 
carriers in order to prevent the birth of beta thalassemia 
newborns is the best method to overcome the problem. 
Unfortunately, due to special economic, social, and 
cultural situations of the province, the prevention of 
BT newborn seems to be too difficult. The objective of 
the present study was to determine the survival of the 
patients with BT major, receiving blood transfusion in 
Sistan & Baluchestan province, Southeast of Iran and 
the factors involved with the survival time.
Methods. This cross-sectional study was performed 
in 2007 in Zahedan, Sistan & Baluchestan province, 
Southeast of Iran. The data were collected using the 
records of a number of 578 patients from all over the 
province referred to the Thalassemia Treatment Center, 
Zahedan, Iran during a period of 8 years from 1998 to 
2006. It is the only center providing different services 
for the patients in the whole province. A number of 
578 patients were diagnosed by the doctors and some of 
them died during the treatment. The inclusion criteria 
were regular visiting of those who were diagnosed as 
thalassemic patients and were referred to the center, and 
the patients who did not visit the center to receive their 
treatments for some time and there were no information 
on their current situation, or those who had applied for 
bone marrow transplantation, were excluded from the 
study. The center was formally established in 1998 and 
a file containing demographic and medical information 
(namely gender, age, ethnicity, the blood group, and RH, 
and the date of death for the dead cases) was opened and 
kept for each patient. The donated blood for transfusion 
is screened against a number of infections such as HIV, 
malaria, hepatitis. The frequency of transfusion depends 
on the hemoglobin (Hb) level; the lower Hb level, the 
more frequently transfusion. Normally, most patients 
receive almost one blood transfusion each month; 
therefore, all of them have to visit the center at lease 
once every month and the number of transfusions is 
recorded regularly. The levels of ferritin and Hb are 
measured every time upon their visit. If they are high, the 
patients receive necessary medicine from the doctors in 
the center. The kind of blood, washed or filtrated (with 
2 different mechanisms in preparing for transfusion) 
was also recorded at the time of transfusion by the staff. 
The patients’ accompanied diseases were another data 
recorded by the doctors at the time of the transfusion. 
The patients have regularly received transfusion since 
the center was established.
For data analysis, the Kaplan-Meyer method, 
and Log Rank test together with Cox Regression in 
Statistical Package for Social Science (SPSS version 15) 
was used to show the survival time and the effect of the 
most important factors involved with their survival. The 
p<0.05 was considered as the significance level. Also, 
the study was approved by the ethical committee of the 
Zahedan University of Medical Sciences.
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Results. The patients included 333 (57.6%) 
males and 245 (42.4%) females, and the 46 dead 
cases included 30 males and 16 females. The patients’ 
survival ranged between a minimum age of few months 
and maximum 43 years with a mean of 10.8, standard 
deviation 6.55 and the median of 10 years. Maximum 
survival was 43 years in male and 25 years in female. 
Regarding the ethnicity, the patients consisted of 211 
Fars, 354 Balouch, and 13 Afghan.  There were 2 kinds 
of transfusion, filtrated blood used in 568 patients 
(98.3%) and washed blood used in 10 patients (1.7%). 
Distribution of the blood groups A, B, O and AB in the 
patients was 22%, 32.9%, 39.1% and 6%, respectively. 
They contained 530 (91.7%) positive and 48 (8.3%) 
negative blood RH. A number of 147 patients (25.4%) 
showed to have the Hb level of ≤9 g/dl with 15 dead 
cases. The number of patients with Hb level of >9 g/dl, 
was 431 (74.6%) with 31 dead.  The mean ± SD of the 
Hb level was 9.8 ± 2.7 with the median of 9.7 g/dl. 
The number of transfusion is usually 12 times in a year 
(monthly transfusion), but in patients with a low level 
of Hb, the number of transfusions was increased. One 
hundred patients (17.3%) had 12 transfusions in a 
year with 10 (21.7%) dead patients, and 478 patients 
(82.7%) had more than 12 times transfusion with 36 
(78.7%) dead ones. The mean ± SD of the number of 
annual transfusions was 14.2 ± 2.82. Concerning the 
level of ferritin, 98 patients (18.6%) grouped as having 
the level of ≤1500 ng/ml, with 5 dead; 394 (75.0%) 
patients had the level of >1500 to 3500 with 29 dead, 
and 33 patients (6.0%) had the level of >3500 with 
9 dead (there are some missing data on ferritin). The 
mean ± SD of ferritin was 2337.6 ± 924.75. A number 
of other diseases (accompanied diseases) such as heart 
disease, renal disease, Hepatitis B and C, and diabetes 
Figure 1 - The survival function of thalassemic patients at Zahedan, Iran 
in 2007.
Table 1 - The frequency of the total and dead patients together with the 
mean, SE and the result of Log Rank test on factors effective 
on survival in 578 Thalassemic patients in Zahedan, Iran 
(2007).
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No death
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  13.5 ± 2.47
  17.0 ± 0.79
0.000
*There are some missing values. SE - standard error
Table 2 - The result of Cox Regression model of the important factors 
effective on the survival of Thalassemic patients in Zahedan, 
Iran (2007).






-0.41 (0.17) 0.018 0.67 (0.47, 0.93)
Number of 
annual transfusions
-0.20 (0.055) 0.000 0.82 (0.74, 0.91)
Accompanied  
diseases
Heart disease 3.12 (0.74) 0.000 22.65 (5.32, 96.49)
Renal disease 3.97 (0.91) 0.000 53.25 (8.9, 318.6)
Hepatitis C 1.84 (0.88) 0.036 6.29 (1.13, 35.02)
Diabetes 2.85 (0.89) 0.001 17.26 (3.03, 98.4)
Diabetes and 
Hepatitis
5.51 (1.28) 0.000 248.21 (20.37, 2023.74)
Liver disorder 3.61( 0.88) 0.000 37.12 (6.67, 206.89)
B - coefficients of regression model, SE - standard errors of the coefficients
CI - confidence interval, Exp (B) = eB
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were observed in some of the patients, especially in the 
dead ones. For example, 27 (58.7%) of the dead patients 
had record of heart diseases in their files.
Figure 1 shows the survival function of thalassemic 
patients. At first year the survival of the patients was 
98.9%. The age survival proportions of the patients 
were 5 (97.9%), 10 (97%), and 15 (92.1%) years. 
(Figure 1). Using Log Rank test, the survival time 
showed significant relationship with the number of 
annual transfusions, the kind of blood, the levels of Hb 
and ferritin, and the accompanied diseases. 
Table 1 shows the factors with their means and SDs 
together with the p-value of Log Rank test. There was no 
significant difference of survival years between different 
genders, different ethnic groups, blood groups, and the 
positive and negative blood RH. 
Table 2 shows the result of Cox regression where the 
survival time is the outcome variable, and the others are 
the predictors. Table 2 shows that if the Hb level increases 
by one, the risk of death reduces approximately by 33% 
and if the number of transfusion increases by one, the 
risk of death reduces by 18%. Also, all accompanied 
diseases (except hepatitis B which had caused no death) 
increase the death hazard. This hazard was the highest 
in diabetes + hepatitis, and it was lowest in hepatitis C.
Discussion. It was found that the survival 
proportions of the thalassemic patients in Southeast of 
Iran until 5 and 10 years of life were 97.9% and 97%, 
respectively. This percentage was reduced to 81.2% by 
the ages of 20 and 59.3% by the ages of 25. This result 
is similar to a recent study in Hormozgan, at South 
of Iran.12 In consistent with some other studies,7,12 no 
significant difference of survival time was seen between 
2 genders, probably because it is a hereditary anemia. 
However, there is a report of significant difference in 
survival time between 2 genders in another study.13 
Significant association was observed between the ferritin 
level and the survival time which is similar to a study 
in Canada.9 Furthermore, the results showed that the 
level of ferritin is related to the disease and a low level 
of ferritin causes heart diseases in thalassemic patients 
as reported previously.7,13 The present study showed no 
association between the patients’ blood groups and the 
survival time. This is in agreement with another study 
that proved no relationship between blood groups and 
the thalassemia result (death-survival), and survival 
time.12 The study also mentioned that the increased 
number of transfusions is an important factor involved 
with the survival time. The survival time increases 
with the increased number of transfusion. This was 
the same as the results of 2 other studies.9,14   Although, 
transfusion is necessary for the patients’ survival and 
this is the best method to suspend the complications of 
the disease, it can cause other problems for the patients 
such as infection transmission, namely Hepatitis B and 
C, HIV, malaria, toxoplasmosis, visceral leishmaniasis. 
Meanwhile, skeletal changes, the disorder of endocrine 
glands, cardiac symptoms, and complications, and renal 
disorders are examples of other disorders which might 
occur soon in these patients.15
There was a relationship between accompanied 
diseases and the survival time. The heart and renal diseases 
were the most causes of the death in the thalassemic 
patients. A study in Italy with 977 patients, showed 
that heart diseases were the cause of death in 67% of 
the thalassemic patients. Of these patients, 6.8% had 
heart failure and 7.5% had cardiac arrhythmia.13 Similar 
to a recent study,12 the survival time was significantly 
different between 2 kinds of transfused blood; the 
patients who received filtrated blood, survived longer 
than those who used washed blood. The results showed 
that the patients with a high level of Hb had a longer 
survival. Since frequent transfusion is necessary for these 
patients’s survival, it is useful to teach the families of 
thalassemic patients to take them to the centers for regular 
transfusions. Also, it is necessary to screen the blood 
before transfusion in order to decrease the incidence of 
infections, especially diseases such as Hepatitis B and C. 
Even if the parents and the authorities do their best to 
reduce the problems of thalassemic patients, the survival 
time and life quality of the patients will remain low, in 
comparison with others. Also, the treatment cost of the 
thalassemia patients is very high and families with low 
income cannot pay the cost. Furthermore, the families 
in Sistan & Baluchestan province have less knowledge 
on the disease and the way of prevention. However, 
the disease is widespread, especially at the borders of 
the country. The best solution for the problem is to 
increase the knowledge of the people on the disease 
and the methods which can be used to prevent it. Also, 
the authorities are strongly recommended to pay more 
attention in arranging screening tests before people’s 
marriages in order to find the carriers and prevent the 
extension of the disease. This mechanism can help to 
find the minor carriers of the disease and prevent the 
marriages which lead to the birth of thalassemic major 
newborns or provide them with necessary advices. Since 
regular recording of the patients’ medical information 
is very important for patients’ health and treatment, 
and this recording had not be carried out appropriately, 
it can be mentioned as one of the limitations of the 
study. For example in some cases the patients’ deaths 
were not recorded regularly, especially in those who had 
died in other hospitals because of the complications of 
thalassemia. 
In conclusion, the authorities of the center are 
recommended to record the patients’ medical data and 
their mortality regularly. Also, the factors which can 
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increase the patients’ survivals should be considered in 
their future treatment. Finally, further researches are 
required to find other factors involved with increasing 
of the patients’ survival.
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